沙利度胺联合CHOP方案治疗淋巴瘤24例的临床观察  

Clinical observation of 24 cases of lymphoma treated by thalidomide combined with CHOP regimen

作　　者：詹扬[1] 姚福生[1] 

机构地区：[1]安庆市立医院血液科,安徽246003

出　　处：《安徽卫生职业技术学院学报》2013年第2期33-33,62,共2页Journal of Anhui Health Vocational & Technical College

摘　　要：目的:观察沙利度胺在侵袭性非霍奇金淋巴瘤(NHL)中的治疗作用及不良反应。方法:24例侵袭性恶性淋巴瘤患者,临床分期按Ann Arbor国际分期,ⅡB期3例,ⅢA期9例,ⅢB期8例,ⅣA期2例,ⅣB期2例。结果:沙利度胺联合CHOP方案治疗NHL有效率为62.5%。结论:该方案适合临床使用,具有进一步临床观察的价值。Objective ： To observe therapeutic effect and adverse reactions of thalidomide in the treatment of ag- gressive non-Hodgkin＇s lymphoma （NHL）.Method：According to the Ann Arbor staging, among 24 cases of invasive malignant lymphomapatients, 3 cases were in Ⅱ B clinical stage, 9 cases Ⅲ A, 8 cases in Ⅲ B,2 cases in Ⅳ A and Ⅳ B Result ：The clinical effective rate was 62.5% for treating N HL with tahlidomide combined with C HOP. Conclusion ：Thalidomide is suitable for clinical use for aggressive non-Hodgkin＇s lymphoma （NHL）, with further clinical observation value.

关 键 词：沙利度胺 淋巴瘤 分期 疗效 

分 类 号：R733.4[医药卫生—肿瘤]